替米沙坦不同联用药方案治疗轻、中度原发性高血压的成本-效果分析  

Telmisartan in Combination with Different Drugs for Mild to Moderate Essential Hypertension:Cost-Effectiveness Analysis

作　　者：张贺功[1] 董传海[2] 邢军[2] 

机构地区：[1]山东莱芜钢铁集团有限公司医院,莱芜市271125 [2]山东莱芜市人民医院,莱芜市271100

出　　处：《中国药房》2007年第35期2728-2730,共3页China Pharmacy

摘　　要：目的:评价替米沙坦不同联用药方案治疗轻、中度原发性高血压的成本-效果。方法:60例患者随机分为3组,分别给予替米沙坦+非洛地平(A组)、替米沙坦+依那普利(B组)、替米沙坦+吲达帕胺(C组)治疗8wk后进行成本-效果分析。结果:A、B、C组总有效率分别为90%、85%、95%;总成本分别为422.80、409.50、348.88元,C组与A、B组比较有显著性差异(P<0.05)。结论:C组方案治疗轻、中度原发性高血压较佳。OBJECTIVE：To evaluate the cost- effectiveness of telmisartan in combination with different drugs in the treatment of mild to moderate essential hypertension.METHODS：A total of 60 patients were enrolled and randomized to Group A （telmisartan ＋ felodipine）, Group B（telmisartan ＋ enalapril）, or Group C（telmisartan ＋ indapamide） .A cost - effectiveness analysis of the three therapeutic schemes was conducted after 8- wk treatment.RESULTS： The effective rates of three Groups were 90%, 85 % and 95 %, respectively; the total costs of three groups were 422.80,409.50 and 348.88 yuan, respectively, with Group C showing significant difference as compared with the other two groups（Group B and Group C）（P 〈 0.05） .CONCLUSION：Group C（telmisartan ＋ indapamide） was the optimal therapeutic schemes for mild to moderate essential hypertension.

关 键 词：替米沙坦 吲达帕胺 非洛地平 高血压 成本-效果分析 

分 类 号：R956[医药卫生—药学] R972.4